Regeneron shares climbed Tuesday, following news of the company being awarded a $450 million contract with the U.S. government, for developing coronavirus treatment.
The biotechnology company said that the contract will support it in boosting production of the REGN-COV2, conditional upon the success of clinical trials and Emergency Use Authorization or product approval from the Food and Drug Administration grants
REGN-COV2 is involved in two different clinical trials for both the treatment and prevention of the COVID-19.
Another biotech company Novavax also received a government contract, worth $1.6 billion from the federal government, to complete late-stage development of its NVX‑CoV2373 Covid-19 vaccine candidate, and to begin large-scale manufacturing and delivery of the drug by next year.
Tickeron's Comparison of Novavax, Inc. (NVAX) vs Regeneron Pharmaceuticals, Inc. (REGN) :
[NVAX & REGN] are closely correlated.
Both companies represent the Biotechnology industry
Market capitalization -- NVAX: $4.6B vs. REGN: $70.6B
Current volume relative to the 65-day Moving Average: NVAX: 37% vs. REGN: 68%
Brand notoriety: NVAX and REGN are both notable
Long term analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVAX’s FA Score shows that 1 FA rating(s) are green while REGN’s FA Score has 3’s green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators.
NVAX’s TA Score shows that 3 TA rating(s) are bullish while REGN’s TA Score has 2’s bullish TA rating(s).
REGN vs NVAX: Fundamental Ratings:
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVAX's Valuation (1) in the Biotechnology industry is significantly better than the same rating for REGN (85). This means that NVAX’s stock grew significantly faster than REGN’s over the last 12 months.
REGN's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for NVAX (100). This means that REGN’s stock grew somewhat faster than NVAX’s over the last 12 months.
REGN's SMR Rating (18) in the Biotechnology industry is significantly better than the same rating for NVAX (100). This means that REGN’s stock grew significantly faster than NVAX’s over the last 12 months.
REGN's Price Growth Rating (4) in the Biotechnology industry is in the same range as NVAX (34). This means that REGN’s stock grew similarly to NVAX’s over the last 12 months.
REGN's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for NVAX (100). This means that REGN’s stock grew significantly faster than NVAX’s over the last 12 months.
The RSI Indicator for REGN moved out of oversold territory on May 30, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In of the 21 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
REGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
REGN moved below its 50-day moving average on May 04, 2023 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for REGN crossed bearishly below the 50-day moving average on May 05, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for REGN entered a downward trend on June 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. REGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.414) is normal, around the industry mean (24.947). P/E Ratio (19.881) is within average values for comparable stocks, (122.964). Projected Growth (PEG Ratio) (1.673) is also within normal values, averaging (4.308). Dividend Yield (0.000) settles around the average of (0.031) among similar stocks. P/S Ratio (6.720) is also within normal values, averaging (307.036).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of medicines for the treatment of serious medical conditions
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.
|VRTX - REGN|
|INCY - REGN|
|ALNY - REGN|
|AMLX - REGN|
|MRNA - REGN|